ANABPDUFA
Imsidolimab (ANB019) (anti-IL-36R)
Hidradenitis suppurativa, Generalized pustular psoriasis, EGFRi-mediated skin toxicity, Ichthyosis, Palmoplantar pustulosis, Acne
Approval decisionFDA regulatory calendar
Track FDA action dates and advisory committee meetings by month. Each event links to its company, drug, indication and source-backed research record.
FDA regulatory calendar
Hidradenitis suppurativa, Generalized pustular psoriasis, EGFRi-mediated skin toxicity, Ichthyosis, Palmoplantar pustulosis, Acne
Approval decisionUse the monthly FDA calendar to review PDUFA target dates and advisory committee meetings, then open each event for drug, company, indication and source context.